A Look at the Vaccine Pipeline

According to Datamonitor Healthcare, it performs better than other traditional inactivated flu vaccines, meaning that in its expected launch for the 2020-2021 flu season it could capture a large part of the elderly population. First approved in 2000, Prevnar 7 was the first pneumococcal conjugate va...

Full description

Saved in:
Bibliographic Details
Published in:Drug Topics 2019-07, Vol.163 (7), p.38-39
Main Author: Hamm, Nicholas
Format: Article
Language:English
Subjects:
Candidates
Cell culture
Disease
FDA approval
Immunization
Influenza
Older people
Seasons
Success
Vaccines
Viruses
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to Datamonitor Healthcare, it performs better than other traditional inactivated flu vaccines, meaning that in its expected launch for the 2020-2021 flu season it could capture a large part of the elderly population. First approved in 2000, Prevnar 7 was the first pneumococcal conjugate vaccine. According to Datamonitor Healthcare, it could achieve this due to its broad serotype coverage- it would be the first vaccine cover serotypes A, B, C, W, and Y, which could allow it to cover a wide range of patient populations. According to Datamonitor Healthcare, it could then charge a premium price if it shows superior immunogenicity to Menactra and Menveo.
ISSN:0012-6616
1937-8157